NCT00605137 is a Phase 3 clinical trial of insulin detemir in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT00605137?

NCT00605137 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT00605137?

Interventions in NCT00605137: insulin detemir, insulin NPH.

What condition does NCT00605137 study?

NCT00605137 studies Diabetes, Diabetes Mellitus, Type 1.

Is NCT00605137 still recruiting?

NCT00605137 is currently completed. Last updated 24 February 2017.

Last reviewed 2017-02-24 · How we verify

NCT00605137

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of Insulin Detemir in Children With Type 1 Diabetes

Completed Phase 3 Last updated 24 February 2017

What this trial tests

Phase 3 trial testing insulin detemir in Diabetes in 83 participants. Completed in 23 April 2005.

Timeline

21 May 2004

Primary endpoint
23 April 2005

23 April 2005

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	83
Start date	21 May 2004
Primary completion	23 April 2005
Estimated completion	23 April 2005
Sites	1 location across Japan

Drugs / interventions tested

insulin detemir (INSULIN DETEMIR) — full drug profile →
insulin NPH — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 7 to 18, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Japan. The aim of trial is to investigate the safety of insulin detemir and insulin NPH in children with type 1 diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B, Metzendorf MI, Richter B. · · 2021 · cited 18× · PMID 33662147 · DOI 10.1002/14651858.cd013498.pub2

Verify or expand the search:

Other trials of insulin detemir

Trials testing the same drug.

NCT02967211 — A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in · Phase 4 · completed
NCT02967224 — A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins i · Phase 4 · completed
NCT01835431 — A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the · Phase 3 · completed
NCT01892319 — An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Wo · completed
NCT01831765 — Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 D · Phase 3 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00605137 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 24 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00605137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing